Molecular profiling is today's answer to the eternal unmet need of personalising anticancer therapy. We have never reached such a level of rationality before, based on new technologies, knowledge of systems biology and insights into patho-mechanisms. Whereas we actually focus mainly on mutations of a limited number of cancer genes, we will also have to integrate epigenetic, transcriptional and post-transcriptional changes into our future therapeutic considerations. Overall, we have reached an advanced level of stratified medicine, but are still on the way of targeting the holy grail of real personalisation.
Molecular profiling is becoming undoubtedly more and more part of the workup of cancer patients. The fact that tumour profiling is not restricted anymore, to be used within the scientific frame to upgrade the level of stratification in clinical trials or to test whether the integration of this methodology, will even allow individualisation of cancer treatment, which makes it necessary to critically define its actual position. Such an attempt of positioning whether, based on its overall scientific accuracy and reliability, its use is justified in the clinical routine is eagerly warranted since it has already been commercially propagated and advertised.
Personalising cancer medicine is a logical path that has been pursued by generations of oncologists. It is based on the trivial finding that individual human beings behave differently in terms of the same pharmacotherapeutic intervention against their similar tumours with regard to histology.
Various methodologies have been developed to individualise anticancer therapy, but none of them, neither the clonogenic assay as published by Von Hoff et al. 1 nor the adenosine-triphosphate (ATP)-based chemosensitivity assay (TCA) used by Cree et al., 2 have been proved to generate superior treatment results in comparison to treatment choice based on the respective best available standard. With molecular profiling, a level of precision medicine has been touched upon that had never been reached before. Nevertheless, the same principal questions have to be asked and confirmed before we are justified to propagate it as the oncologic panacea of the 21st century.
In a first attempt in this direction, Cobo et al., 3 who compared standard treatment with biomarker-based selected chemotherapy in non-small cell lung cancer, only found an advantage for objective response, but not for progression-free and overall survival (PFS/OS).
Large screening programmes have been set up at renowned institutions worldwide to offer patients clinical trials evaluating drugs that matched specific identified molecular alterations determined with different technologies. Retrospective analyses of such trial programmes turned out to provide generally results of improved outcome compared with historical controls. [4] [5] [6] There are different types of ongoing trials using molecular profiling prospectively. According to Le Tourneau et al. 7 they can be subdivided into stratified and algorithm-based ones. The stratified trials are mainly disposing on the V600E BRAFmut and the ALK/MET activation, respectively, are still actively recruiting patients as does the National Cancer Institute -Molecular Analysis for Therapy Choice (NCI-MATCH) initiative, which is not restricting molecular alterations to be tested.
Algorithm-based trials aim to prove that treatment according to the test results of molecular profiling yields better outcome than standard therapy. Two out of three single-arm trials, the study endpoint of which was prolonging the individual PFS reached on the base of molecular profiling versus the individual previous one under standard therapy, have been successfully completed and have shown to be feasible. 8, 9 However, none of the several prospective randomised trials that represent the only methodologically convincing ones to falsify the hypothesis of superiority has been completed up-to-date. The most advanced of them, the SHIVA-trial, was proved to be feasible, 10 cancer cells leading to cancer growth and therapy tolerance has been described recently. 11 It is a matter of speculation whether epigenetic therapy, modulation of microenvironment or immunotherapy will be able to overcome this challenge. n
